MedTrace Logo

Development of an Exergame to Deliver a Sustained Dose of High-Intensity Training

NCT03477773 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-03-26

No results posted yet for this study

Summary

Males from areas of social deprivation within the town of Middlesbrough (UK) were targetted and recruited on to a high-intensity, exergaming intervention over a 6-week period. Eligible participants were randomly allocated to an intervention group (weekly exergaming) or control group (normal habitual lifestyle). All participants completed baseline (week 0) and follow-up (week 7) measures of metabolic health. Participants in the intervention group were invited to three sessions a week of high-intensity exergaming performed against their peers on a developed boxing game.

Conditions

  • Metabolic Syndrome

Interventions

OTHER

High-intensity exergaming

Perform high-intensity exercise whilst playing a developed exergame. A full warm-up performed prior to the session was performed (\~70% HRmax). Periods of exercise were performed at an intensity \>85% HRmax for periods of 10, 20 and 30s, interspersed with periods of rest, for a total of 2-3 minutes per session. Heart rate was monitored throughout the intervention.

Sponsors & Collaborators

  • Teesside University

    collaborator OTHER

  • Northumbria University

    collaborator OTHER

  • Newcastle University

    collaborator OTHER

  • Sheffield Hallam University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-01
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03477773 on ClinicalTrials.gov